SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Rodec Pharma gets SEBI’s approval to float IPO

30 May 2026 Evaluate

Rodec Pharma has got the Securities and Exchange Board of India’s (SEBI) approval to raise funds through initial public offering (IPO). The company’s maiden public offering will be entirely an offer-for-sale of 56.5 lakh shares by promoter Mukesh Kumar Gupta. Hence, the company will not receive any funds from the offer.

The company had filed its draft papers in January 2026. Shares of the company are proposed to be listed on the BSE and the NSE. In SEBI's parlance, obtaining observations is equivalent to securing approval to float a public offering.

Rodec Pharma, incorporated in 1997, is engaged in the manufacturing of animal feed supplements and marketing of veterinary pharmaceutical drugs and animal feed supplements to address healthcare and nutritional requirements of livestock animals under the for the animal healthcare sector.

Peers
Company Name CMP
Sun Pharma Inds. 1787.10
Dr. Reddys Lab 1271.75
Cipla 1376.25
Zydus Lifesciences 1097.90
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×